Clinical Trials Browser

Phase 2 × INDUSTRY × cediranib × Clear all

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02889900 2022-03-08

CONCERTO

Phase 2 Completed

62 enrolled 15 charts

Ovarian Neoplasms

NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Phase 2 Completed

105 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT00454805 2016-08-03

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

Phase 2 Completed

75 enrolled 11 charts

Advanced Breast Cancer

NCT00306891 2012-11-01

Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)

Phase 2 Completed

60 enrolled 13 charts

Neoplasms

NCT00278889 2012-10-24

HORIZON I

Phase 2 Completed

215 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT00385203 2012-07-16

The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).

Phase 2 Completed

35 enrolled 13 charts

GastrointestinalSarcoma

Neoplasms, Sarcoma, Gastrointestinal Stromal Tumors